Welcome to our dedicated page for CHARLES RIVER LABORATORIES INTERNATIONAL SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHARLES RIVER LABORATORIES INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHARLES RIVER LABORATORIES INTERNATIONAL's regulatory disclosures and financial reporting.
Charles River Laboratories International, Inc. executive Michael Gunnar Knell, CSVP, CAO and Interim CFO, reported equity-related transactions in company common stock. On January 30, 2026, he acquired 1,668 shares at $0 per share, reflecting performance share units earned from awards granted on May 26, 2023.
On the same date, Knell disposed of 526 shares of common stock at $211.68 per share. After these transactions, he directly held 14,602 shares of Charles River Laboratories common stock.
Charles River Laboratories International executive Mark Mintz, EVP and Chief Information Officer, reported equity compensation activity in company stock. On January 30, 2026, he acquired 1,797 shares of common stock at $0, issued after meeting performance goals from performance share unit awards granted on May 26, 2023. On the same date, 655 shares of common stock were disposed of at $211.68 per share under transaction code F. Following these transactions, Mintz directly owned 7,492 shares of Charles River common stock.
Charles River Laboratories International, Inc. officer Shannon M. Parisotto reported equity award activity in company stock. On January 30, 2026, Parisotto acquired 4,236 shares of common stock at $0 per share following the achievement of performance goals under performance share unit awards originally granted on May 26, 2023.
On the same date, 1,067 shares of common stock were disposed of at $211.68 per share, typically reflecting shares withheld to cover taxes. After these transactions, Parisotto directly held 15,184 shares, and indirectly held 982 shares through a revocable trust and 28,510 shares through Karpathos Investments LLC.
Charles River Laboratories International executive reports small stock sale. Executive Vice President of Corporate Strategy & Development Joseph W. LaPlume sold 400 shares of the company's common stock on 08/22/2025 at a price of $163.72 per share. After this transaction, he directly beneficially owned 23,716 shares of Charles River Laboratories common stock.
Charles River Laboratories International outlined improving demand and strategic moves ahead of a major healthcare conference. The company reported that demand in its Discovery and Safety Assessment (DSA) segment strengthened through the second half of 2025, with a preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter, meaning new DSA bookings exceeded revenue.
For 2026, the company expects the top end of its organic revenue growth guidance ranges to be at least flat for both the consolidated business and the DSA segment, with a cautious expectation of returning to revenue growth in the second half of 2026. Foreign exchange is expected to add 100–150 basis points to reported revenue growth, and incremental cost savings of more than $100M in 2026 are intended to offset cost inflation and support non-GAAP operating margin.
The company also plans two acquisitions: the assets of K.F. (Cambodia) Ltd. for about $510M, expected to be accretive to non-GAAP EPS by about $0.25 in 2026 and $0.60 in 2027, and the remaining 79% of PathoQuest SAS for €51.6M (about $60M), which is expected to generate $15–$20M of 2026 revenue but not materially affect 2026–2027 financial results.
Charles River Laboratories International, Inc. announced a planned leadership transition. On May 5, 2026, Chief Operating Officer Birgit Girshick will become Chief Executive Officer, succeeding James C. Foster, who will step down as CEO and Chair and is expected to remain a non-executive director. Lead Independent Director Dr. Martin Mackay is expected to become Chair of the Board on the same date.
Ms. Girshick’s compensation will be adjusted for her new role, with base salary set at $1,200,000 effective February 1, 2026, a target annual cash incentive equal to 100% of base salary effective May 1, 2026, and an initial equity grant with a target fair market value of $9,000,000, mostly in performance share units. In connection with a potential change in control, she would be eligible for severance equal to three times salary plus target bonus, three years of benefits, and outplacement services if terminated under specified conditions.
The Board size will increase from 11 to 12 directors as of the transition date to add Ms. Girshick, with consent from Elliott-affiliated funds under an existing cooperation agreement. Mr. Foster will receive restricted stock units with an underlying fair market value of $3,000,000, expected to be granted on March 2, 2026, vesting after two years, and is expected to receive standard non-executive director compensation thereafter.
Charles River Laboratories International, Inc. reported that demand indicators in its Discovery and Safety Assessment (DSA) segment are improving. At an investor presentation at the Evercore 8th Annual Healthcare Conference, management stated that DSA net book-to-bill has improved each month since the beginning of the third fiscal quarter of 2025. The company also noted that typical holiday seasonality in the fourth quarter and early January could affect near-term proposal and booking activity, but emphasized its encouragement with the positive momentum and upward trends observed since the middle of fiscal 2025.
Charles River Laboratories International, Inc. (CRL) announced the conclusion of an SEC investigation without an enforcement recommendation. The SEC’s Division of Enforcement informed the company that, based on the information available to it, it does not intend to recommend an enforcement action related to the company’s sourcing of non-human primates and related disclosures. The company’s Audit Committee also completed its own independent investigation into the same matters, reporting no material findings. This removes a regulatory overhang that had been disclosed since May 2023.
Charles River Laboratories (CRL): Schedule 13G/A reports that Nomura Holdings, Inc. beneficially owns 807,923 shares of CRL common stock, equal to 1.6% of the class. The ownership is held with sole voting and dispositive power and is attributed to Nomura subsidiaries Nomura Global Financial Products, Inc., Nomura Securities International, Inc., and Nomura International PLC.
The percentage is based on 49,215,000 shares outstanding as of September 27, 2025. Nomura certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Charles River Laboratories (CRL): Schedule 13G/A ownership update. Wellington Management Group LLP and affiliated entities filed Amendment No. 2 reporting beneficial ownership of 3,190,467 shares of CRL common stock, representing 6.48% of the class as of the event date 09/30/2025. The filing indicates shared voting and shared dispositive power across Wellington entities, with no sole voting or dispositive power reported.
The certification states the shares were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. The securities are held of record by clients of Wellington’s advisory affiliates, and no such client is known to hold more than five percent of the class.